CDER Benefit/Risk Assessment Tool Has Room For OTC Considerations
This article was originally published in The Tan Sheet
Executive Summary
A new benefit/risk framework for drug reviews currently being tested in FDA requires incremental considerations to apply to OTC reviews, a CDER official says. Former NDAC chairman Brass says FDA’s model is compatible with a separate OTC assessment framework developed for industry.